Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms.

[1]  K. Fukuda,et al.  Synergistic induction of eotaxin expression in human keratocytes by TNF-alpha and IL-4 or IL-13. , 2000, Investigative ophthalmology & visual science.

[2]  M. Abelson,et al.  Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. , 1999, Acta ophthalmologica Scandinavica. Supplement.

[3]  M. Abelson,et al.  The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model. , 1999, Acta ophthalmologica Scandinavica. Supplement.

[4]  P. Lieberman,et al.  Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. Rhinitis Study Groups. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[5]  S. Xu,et al.  Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. , 1999, Archives of ophthalmology.

[6]  M. Abelson.  Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[7]  Mitchell H. Friedlaender.  The current and future therapy of allergic conjunctivitis. , 1998, Current opinion in ophthalmology.

[8]  M. Abelson,et al.  Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. , 1998, American journal of ophthalmology.

[9]  Jaanus Sd.  Oral and topical antihistamines: pharmacologic properties and therapeutic potential in ocular allergic disease. , 1998 .

[10]  J. H. Day,et al.  Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. , 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[11]  G. Guyatt,et al.  Interpretation of rhinoconjunctivitis quality of life questionnaire data. , 1996, The Journal of allergy and clinical immunology.

[12]  R. Gerth van Wijk,et al.  The relationships between nasal hyperreactivity, quality of life, and nasal symptoms in patients with perennial allergic rhinitis. , 1996, The Journal of allergy and clinical immunology.

[13]  M. Friedlaender,et al.  A review of the causes and treatment of bacterial and allergic conjunctivitis. , 1995, Clinical therapeutics.

[14]  M. Abelson,et al.  Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. , 1993, Survey of ophthalmology.

[15]  G. Guyatt,et al.  Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis , 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[16]  J. Yanni,et al.  The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. , 1996, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[17]  Jaanus Sd,et al.  Ocular side effects of selected systemic drugs. , 1992 .